The first day of Nordic Life Science Days (NLSDays) 2023 has come to an end and it offered interesting discussions on business strategies and health data, Nordic scientists presenting their
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
Advertisement
NLS News
Valo Therapeutics received approval from Germany’s PEI (Paul Ehrlich Institute) to extend the tumor types to be treated in the company’s current Phase I trial into two subtypes of sarcoma.
Advertisement
The previous founder and CEO of BioLamina has gone back to business development, and with his newly founded company he aims to redefine cell therapy development even further. Newly founded
Christmas is around the corner. At least that is what it feels like every year by the time I get around to look into gifts for my family. So, this
Calliditas’ partner Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has approved Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of
Xbrane Biopharma is focusing the company’s development portfolio and, consequently, the development of Xtrudane (biosimilar candidate to Keytruda) has been terminated. Furthermore, a cost-savings scheme is being introduced which is
Novo Nordisk has announced the investment of more than EUR 2.1 billion euros starting in 20231 to expand the existing production site in Chartres, France, for the current and future
North Carolina (NC) State University and the Danish Technical University (DTU) have the goal to establish a world-class program in bioprocess R&D and workforce training. NLS asked Jennifer Hemphill, Industry
Advertisement
ADDvise Group has entered into a share purchase agreement with the owner of Axelerist regarding the acquisition of all shares of Axelerist. Closing of the acquisition takes place today, Nov
An independent Data Monitoring Committee (DMC) has completed the planned dose selection analysis including safety review and assessment for futility in Induction Study 1 of the phase III program CONCLUDE.
Texray has announced the successful completion of an investment round led by Industrifonden and supported by private investors at Impilo. This round significantly exceeded expectations, highlighting the robust investor interest
Vironova BioAnalytics has announced its acquisition led by QuatreLab (a quality control company created by Columbus Venture Partners) with the participation of Accord Investment Partners and Venture Targeter AB. Following
Over the past ten years, the life science industry across the Nordics has shown tremendous growth. Despite some hiccups along the way caused by global upheavals, the region’s industry continues
Lecanemab was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023. The Scrip Awards celebrate the best innovations and
Sponsored content
Octreotide – A Complex Molecule for a Complex Disease
Octreotide acetate is a therapeutic octapeptide analog of the naturally occurring hormone somatostatin. It is used for the reduction of growth hormone and insulin-like growth factor 1 primarily used in adults with acromegaly.
New therapies such as oral formulations promise better disease control and quality of life for patients but require 30-60 times higher octreotide acetate concentrations, thus putting demand on complex API manufacturers such as Bachem to cost-effectively scale production.
Drug and Device Development
Ultimovacs has announced encouraging overall survival (OS) data from cohort 1 in the UV1-103 Phase I clinical trial in malignant melanoma. Among the patients in cohort 1 who were alive
Valo Therapeutics received approval from Germany’s PEI (Paul Ehrlich Institute) to extend the tumor types to be treated in the company’s current Phase I trial into two subtypes of sarcoma.
Alzinova has reported positive top-line results from its phase 1b clinical trial of the vaccine candidate ALZ-101 in Alzheimer’s disease. “The positive top-line results further strengthen our confidence in that
The US market
The Life Science Bridge is a joint initiative between the regional Swedish American Chambers of Commerce in San Diego, Boston, San Francisco and Minnesota, supporting Scandinavian life science companies looking
The Nordic AMPlify program, available to promising Nordic digital health and medtech companies, aims to shorten time to market, kickstart a successful US growth journey and initiate co-development, partnerships, and
Norwegian DNB Bank and US Back Bay Life Science Advisors have entered a partnership to combine scientific and strategic expertise with financing origination and execution capabilities. NLS asked Jonathan Gertler,
“US investors are looking for a large market opportunity, relevant clinical evidence, and a plan with a team that can execute.” – Felicia Steinunnsdóttir, Swedish American Chamber of Commerce
Upcoming events
Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world
An official side event of Slush for Life Sciences. Y Science will gather together the life science community at Slush, to connect researchers, startups, investors, students, and all those enthusiastic
For eight years, the DNB Nordic-American Healthcare Conference (formerly the Nordic American Life Science Conference) has been the leading US forum for US-Nordic healthcare investment and growth, bringing together promising
This is the 12th edition of this partnering event for early stage deals and investor rounds in the life science field. The first day of the event will include a
Careers
Promotions and hefty raises do not create leaders. While some people always want to sit in the driver’s seat, leadership – effective leadership – is a learned skill. Too often
Professor of Biometry, Samuli Ripatti, has been appointed the new Director of the Institute for Molecular Medicine Finland (FIMM). According to Jari Koistinaho, Director of the Helsinki Institute of Life Sciences
SciBase Holding has announced that the Board has appointed Pia Renaudin as the company’s Chief Executive Officer (CEO). Simon Grant resigned from his position as CEO for personal reasons and
Careers
For some people, testing the same thing over and over – tweaking, refining and then trying again – would seem tedious. For Charlotte Aagaard, however, trial-and-error to obtain final results
JOB ALERTS
Read the latest issue of our magazine!
No 04 2023 // This Nobel Prize-special issue includes for example exclusive interviews with Medicine Laureate Katalin Karikó and Chemistry Laureate Moungi Bawendi, as well as in-depth articles about their discoveries and their impact – not least bringing forth an effective vaccine against the devastating COVID-19 virus.
This issue also includes hopeful news from our Nordic region, in the form of five different life science strengths; a globally unique science study, a successful entrepreneur, a biotech powerhouse, a frontrunner within quantum computing and a promising startup. We also highlight efforts and initiatives when it comes to collaboration across borders and projects making the most out of our different strongholds. After all, we are quite small nations, but together our voice can be heard and our impact and prosperity is larger.
In the new section My Nordic Corner we have spoken to four different companies about their hometown’s life science vibe and what quality of life each offers. This, and much more, in our latest issue!
Profile
When considering the significant industries in Norway, several obvious ones spring to mind: oil and gas, hydropower, property, and fishing. Life sciences would feature on very few lists, but that
In the heart of Iceland’s life sciences industry, Jonina Gudmundsdottir, the CEO of Coripharma, is making her mark. With a deep understanding of the industry’s challenges and a relentless drive
The CEO of Lundbeck, who announced that she will retire last week, did not initially intend to join the life science industry, but it captivated her more than 30 years
The latest research news from the Nordic region
Science articles
An international team of scientists led by the University of Helsinki performed comprehensive mapping of structural alterations in cellular proteins during the aging process. In the study published in Molecular
The 2023 Ig Nobel Prizes celebrates for example backward reading and counting nostril hairs. The 2023 Ig Nobel Prizes were awarded at the 33rd First Annual Ig Nobel Prize ceremony,
Researchers at Karolinska Institutet have developed a molecular method able to detect whether or not bacteria respond to antibiotics within minutes. The findings are presented in the journal Nature Microbiology
Professor Jens Juul Holst has made discoveries that have strongly influenced how people with obesity or type 2 diabetes are treated today. Throughout a long career, this internationally recognized researcher
Professor Åslaug Helland is the recipient of the King Olav Vs Cancer Research Award 2023. “This is a great honor, and I am very happy about this recognition of the
In January 2023, the European Association for the Study of Obesity (EASO) and the Novo Nordisk Foundation (NNF) announced that they were establishing a new prize for an agenda-setting researcher
Nordic Life Science
The latest clinical trials
Valo Therapeutics received approval from Germany’s PEI (Paul Ehrlich Institute) to extend the tumor types to be treated in the company’s current Phase I trial into two subtypes of sarcoma.
Alzinova has reported positive top-line results from its phase 1b clinical trial of the vaccine candidate ALZ-101 in Alzheimer’s disease. “The positive top-line results further strengthen our confidence in that
The company has announced data from part 2 of its international multi-center CORIST open label phase IIa trial. The 25 enrolled patients in CORIST part 2 were heavily pretreated and
An independent Data Monitoring Committee (DMC) has completed the planned dose selection analysis including safety review and assessment for futility in Induction Study 1 of the phase III program CONCLUDE.
The company has announced positive results from its Phase 1a clinical trial in healthy subjects. The clinical trial demonstrated favorable safety and tolerability, fast uptake of HER-096, and significant HER-096
FluoGuide has reported positive topline efficacy and safety results in the trial with the lead product FG001 for guiding surgery in aggressive brain cancer (high-grade glioma). “I am pleased with
The company has announced topline results from the phase IIa trial of its lead product FG001 in guiding surgery in patients with head & neck cancer, confirming positive efficacy and
The company has presented Phase I data on its TILT-123 monotherapy, a T-cell activating oncolytic virus for advanced solid tumor patients, in a late-breaking poster at the Society for Immunotherapy
SynAct Pharma has announced evaluation of the 4-week RESOLVE Phase 2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate. During the evaluation
Sign up to our newsletter
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
Advertisement
